非结核分枝杆菌肺病抗菌素治疗以外的综合治疗研究进展  

Research progress on comprehensive treatment beyond antibiotic therapy for nontuberculous mycobacterium pulmonary disease

作　　者：谭守勇[1] Tan Shouyong(National Key Laboratory of Respiratory Disease,Guangzhou Key Laboratory of Tuberculosis Research,Tuberculosis Department of Guangzhou Chest Hospital,Tuberculosis Prevention and Control Institute of Guangzhou Medical University,Guangzhou 510095,China)

机构地区：[1]呼吸疾病全国重点实验室,广州市结核病研究重点实验室,广州市胸科医院结核内科,广州医科大学结核病防治研究院,广州医科大学,广州510095

出　　处：《中国防痨杂志》2024年第8期967-970,共4页Chinese Journal of Antituberculosis

基　　金：“十三五”国家科技重大专项(2018ZX10722301-001)。

摘　　要：近年来,非结核分枝杆菌(nontuberculous mycobacteria,NTM)感染引起的肺部疾病发病率和患病率呈快速上升趋势。然而,非结核分枝杆菌肺病(nontuberculous mycobacteria pulmonary disease,NTM-PD)存在治愈率低、病亡率高和复发率高的特点。因而,有学者提出,临床医生在治疗NTM-PD时,应该首先管理患者宿主因素,处理好NTM-PD的可控特性,然后优化抗NTM治疗。笔者就近期有关NTM-PD抗菌素以外综合治疗的现状进行综述,提出在治疗NTM-PD的过程中,强化抗菌素以外的综合治疗,减少或避免接触NTM环境,提高机体的免疫力和改善结构性肺病所引起的肺部内环境,是提高疾病治愈率和降低复发率的重要措施。In recent years,the incidence and prevalence of pulmonary disease caused by non-tuberculous mycobacteria(NTM)infection have been increasing rapidly.However,non-tuberculous mycobacterial pulmonary disease(NTM-PD)has the characteristics of low cure rate,high case fatality rate and high recurrence rate.Therefore,some scholars have proposed that clinicians should first manage the host factors and handle the controllable characteristics of NTM-PD,followed by optimizing anti-NTM treatment.This paper provides a review of the current status of comprehensive treatment beyond antibiotic therapy for NTM-PD,and propose that the important measures to improve the cure rate and reduce the recurrence rate of the disease are as follows:strengthening the comprehensive treatment beyond antibiotic therapy during treating NTM-PD,reducing or avoiding exposure to the NTM environment,enhancing the body’s immunity and improving the pulmonary internal environment caused by structural lung disease.

关 键 词：分枝杆菌感染 肺疾病 综合疗法 免疫 

分 类 号：R563[医药卫生—呼吸系统] R459.9[医药卫生—内科学]